A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 20 Mar 2023
At a glance
- Drugs MRG 002 (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Miracogen
- 16 Mar 2023 Planned number of patients changed from 290 to 350.
- 23 Feb 2023 Protocol amended due to changes in study phase, primary outcome, treatment arm and planned patient number as per ClinicalTrials.gov: US National Institutes of Health record.
- 23 Feb 2023 Planned number of patients changed from 60 to 290.